Bio/Pharma Business

After a year that has endured the devastating effects of global economic recessions, corporate bankruptcies, lay-offs and reorganizations, the need for a stable work environment has been steadily moving toward the top of every employee's list of priorities. Industry analysts have been carefully watching for signs of how these factors, and the responses to them from government and regulatory agencies, may ultimately affect the corporate job environment as a whole. The following results of the fifth annual international employment survey show that while the pharmaceutical industry remains strong, its employees are only cautiously optimistic.

December's Contract Services articles include "Using Virtual Private Networks to Gain Competitive Advantage," by Mark Tuomenoska and "Outsourcing Outlook," by Jim Miller.

More than 1600 industry employees report about the status of their current work environment, including salary, job environment, and outlook for next year.

November's Contract Services articles include "Outsourcing Xbox Manufacturing," by Heather Hayes, "Outsourcing Outlook," by Jim Miller, and "Quality in Pharmacovigilance," by Brian Edwards and Jeffrey Priem.

The European Union is attempting to reform its current business environment in hopes of restoring its role in the lobal R&D sector.

The author discusses the potential effect on CROs of pending major-pharma mergers and consolidations.

When choosing a CRO, take the time to conduct an in-depth evaluation of each department, paying special attention to the quality and training of its personnel.

The author examines the concept of evaluating CRO operating performance in today's pharmaceutical industry.

The results of this 2002 survey of contract services decision makers reviews and forecasts the state of the outsourcing industry.

Carefully crafted outsourcing arrangements allow companies to become powerful partners in the quest for market share.

The author discusses the Japanese cabinet's approval of a measure that lifts manufacturing restrictions on domestic pharmaceutical companies.

Brand and product security technologies offer pharmaceutical manufacturers anticounterfeiting solutions.

The author discusses the upcoming human research congressional debate and CROs' preparations to respond.

The author discusses the current soft demand and excess capacity in the contract-manufacturing market of small molecule actives and intermediates.

The author discusses three current examples of new ideas in formulating outsourcing arrangments.

The author discusses current economic times and conditions for large pharmaceutical companies.

The author looks ahead to what 2002 may have in store for the contract services industry.

Capacity is a pivotal commodity in the contract manufacturing business. If you have enough of the right kind of capacity, it's like platinum; conversely, too much of the wrong kind of capacity is like tin.

Recovery of the contract services industry picked up steam in the quarter ending 30 June 2001.

This project­based quality­improvement program uses short­term goals to achieve the long­term objectives of constant, continuous improvement.

The consolidation of the contract manufacturing industry has spread to the parenteral fill-finish segment, with two deals announced just before this year's Fourth of July holiday.

The vulnerability of both the sponsors and the contractors has increased tremendously.

The author reviews year-to-date progress and growth in the pharmaceutical outsourcing industry.